NCT00191113

Somatropin Treatment to Final Height in Turner Syndrome

Humatrope Treatment to Final Height in Turner's Syndrome

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 154 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: Female
• Age: 7 Years – 13 Years
• Healthy volunteers: Not accepted

Summary

A randomized, controlled trial in girls with Turner syndrome at least 7 years old and younger than 13 at study entry, to determine the efficacy and safety of Humatrope (somatropin) treatment in promoting linear growth to final height.

Detailed description

A randomized, controlled trial of Humatrope (somatropin) treatment in girls with Turner syndrome at least 7 years old and younger than 13 at study entry. Core study objectives are to determine the efficacy of Humatrope in promoting linear growth to final height in girls with Turner syndrome, and to assess the safety of this treatment. Core study completion criteria (protocol final height) are that the patient has both a height velocity \< 2 cm per year and a bone age of 14 years or greater. Addendum 1 provides the option of Humatrope treatment to patients who were randomized to the Control arm of the Core study and who discontinued from the study on or after December 19, 1997. Addendum 2 objectives are: 1) to collect true final height data; 2) to evaluate hearing, tympanic membrane function and other specific areas of interest with respect to the safety of growth hormone therapy in Turner syndrome; 3) to evaluate pancreatic beta cell function (glucose metabolism) in patients previously enrolled in the Core study. Addendum 3 objective is to determine the parental origin of the retained X chromosome of an appropriate subset of patients currently or previously enrolled in the Core study, and to determine whether this parental origin holds any predictive value for spontaneous growth or for response to growth hormone therapy.

Conditions

• Turner Syndrome

Interventions

Type	Name	Description
DRUG	Somatropin	0.05 mg/kg/dose by subcutaneous injection 6 times per week, until Core study completion criteria are met (protocol final height).
DRUG	Ethinyl estradiol	escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.
DRUG	Medroxyprogesterone acetate	10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.

Timeline

• Start date: 1989-02-01
• Primary completion: 2007-12-01
• Completion: 2007-12-01
• First posted: 2005-09-19
• Last updated: 2010-01-27
• Results posted: 2010-01-27

Locations

14 sites across 1 country: Canada